Molecular Instruments

Executive Summary

Molecular Instruments has developed HCR™ (Hybridization Chain Reaction), a proprietary technology that enables simultaneous, multiplex, quantitative, high-resolution imaging of RNA and proteins in intact tissues. Unlike traditional in situ hybridization and immunofluorescence methods, HCR uses a one-step, isothermal, enzyme-free signal amplification process, significantly reducing complexity and variability. This platform is positioned to transform spatial biology by allowing researchers to analyze dozens of targets in their native anatomical context, with applications in basic research, drug development, and clinical diagnostics. The company is privately held, founded in 2015, and based in Los Angeles, with a focus on the diagnostics and proteomics markets. While competitive pressures exist from established spatial transcriptomics players, Molecular Instruments' unique enzyme-free, multiplexing capability offers a differentiated value proposition for high-plex spatial analysis.

Upcoming Catalysts (preview)

• Q4 2026Series A or B Funding Round70% success
• Q1 2027Strategic Partnership with Major Pharma60% success
• Q2 2027Launch of Clinical Diagnostic Product40% success